



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|--|
| (51) International Patent Classification ⁶ : A01N 1/02 | A1 | (11) International Publication Number: WO 96/19918 (43) International Publication Date: 4 July 1996 (04.07.96) |
| (21) International Application Number: PCT/US95/16680 (22) International Filing Date: 19 December 1995 (19.12.95) (30) Priority Data: 08/364,699 28 December 1994 (28.12.94) US (71) Applicant: BIOTIME, INC. [US/US]; 935 Pardee Street, Berkeley, CA 94710 (US). (72) Inventors: SEGALL, Paul, E.; 1003 Middlefield Road, Berkeley, CA 94708 (US). WAITZ, Harold, D.; 21 Hillside Court, Berkeley, CA 94704 (US). STERNBERG, Hal; 1735 Spruce Street #4, Berkeley, CA 94709 (US). (74) Agent: GREGG, Valeta; Fish & Richardson P.C., Suite 100, 2200 Sand Hill Road, Menlo Park, CA 94025 (US). | | (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: PLASMA EXPANDERS AND BLOOD SUBSTITUTES (57) Abstract Solutions are described which are useful as plasma expanders and blood substitutes in mammals, including primates, and methods for using the solutions. <i>no information</i> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia | GB | United Kingdom | MW | Malawi |
| AT | Austria | GE | Georgia | MX | Mexico |
| AU | Australia | GN | Guinea | NE | Niger |
| BB | Barbados | GR | Greece | NL | Netherlands |
| BE | Belgium | HU | Hungary | NO | Norway |
| BF | Burkina Faso | IE | Ireland | NZ | New Zealand |
| BG | Bulgaria | IT | Italy | PL | Poland |
| BJ | Benin | JP | Japan | PT | Portugal |
| BR | Brazil | KE | Kenya | RO | Romania |
| BY | Belarus | KG | Kyrgyzstan | RU | Russian Federation |
| CA | Canada | KP | Democratic People's Republic of Korea | SD | Sudan |
| CF | Central African Republic | KR | Republic of Korea | SE | Sweden |
| CG | Congo | KZ | Kazakhstan | SG | Singapore |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovakia |
| CM | Cameroon | LR | Liberia | SN | Senegal |
| CN | China | LT | Lithuania | SZ | Swaziland |
| CS | Czechoslovakia | LU | Luxembourg | TD | Chad |
| CZ | Czech Republic | LV | Latvia | TG | Togo |
| DE | Germany | MC | Monaco | TJ | Tajikistan |
| DK | Denmark | MD | Republic of Moldova | TT | Trinidad and Tobago |
| EE | Estonia | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | UG | Uganda |
| FI | Finland | MN | Mongolia | US | United States of America |
| FR | France | MR | Mauritania | UZ | Uzbekistan |
| GA | Gabon | | | VN | Viet Nam |

- 1 -

PLASMA EXPANDERS AND BLOOD SUBSTITUTESField of the Invention

5 The present invention relates generally to aqueous solutions and methods for using aqueous solutions to perfuse a mammalian subject in need of perfusion and which act as effective substitutes for blood.

Background of the Invention

10 Two clinically applied preservation methods for organs are known: (1) initial perfusion for about 5 min with subsequent cold storage (2°C), and (2) continuous perfusion using aqueous solutions.

 Many of the solutions used for initial perfusion
15 with subsequent cold storage are based on the solutions of Collins et al. (1969) Lancet 2:1219 and Sacks et al. (1973) Lancet 1:1024 (see also, Ross et al. (1976) Transplantation 21:498, Wall et al. (1977) Transplantation 23:210, Bishop & Ross (1978)
20 Transplantation 25:235, Fischer et al. (1985) Transplantation 39:122, Belzer et al. (1985) Transplantation 39:118, Kallerhoff et al. (1985) Transplantation 39:485, and Klebanoff & Phillips (1969) Cryobiology 6:121).

25 Segall et al. (U. S. Patents No. 4,923,442 and 5,130,230) describe blood substitute capable of maintaining a subject and its organs at temperatures below 20°C composed of two to four solutions - a base solution, a cardioplegia-inducing solution, a
30 cardioplegia-maintaining solution, and a recovery solution, with potassium ion concentrations ranging from 4-45 mEq.

- 2 -

Summary of the Invention

The invention features solutions and methods for their use as plasma expanders and blood substitutes in mammals, including primates.

5 Accordingly, the invention features a solution to replace all or a portion of the blood of a mammalian subject, including a primate, comprising K^+ , Mg^{++} , Na^+ , Ca^{++} , Cl^- ; one or more water soluble oncotic agents; an organic carboxylic acid or salt thereof; and
10 physiological levels of a sugar, with the proviso that the solution does not contain a conventional biological buffer.

The solutions of the invention may be used to replace all or a portion of the blood of a mammalian
15 subject, including a primate, at normal temperatures or at temperatures substantially below those normally maintained by a mammal, generally less than 37° - $38^{\circ}C$ and greater than $-2^{\circ}C$.

In one embodiment, the solution includes one or
20 more water soluble oncotic agents selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 70, dextran 40, albumin, and mannitol.

By the term "water soluble oncotic agent" is meant
25 a molecule whose size is sufficient to prevent its loss from the circulation by readily traversing the fenestrations of the capillary bed into the interstitial spaces of the tissues of the body. Examples of water soluble oncotic agents include starches, proteins, and
30 sugars.

The use of blood-free plasma expanders and blood substitutes may result in substantial hemodilution. This is of concern because it may place a subject at risk for hemorrhage. It would be advantageous to administer a

- 3 -

blood clotting factor to a subject undergoing blood substitution. Also, when a subject has undergone substantial blood loss and continues to lose blood, it would be advantageous to administer both a blood substitute and a blood clotting factor. Accordingly, one aspect of the invention encompasses blood substitute solutions containing a blood clotting factor. Another aspect of the invention encompass a method of administering a blood substitute followed by or with the simultaneous administration of a blood clotting factor. Preferably, the blood clotting factor is selected from the group consisting of vitamin K, Factors I, II, V, VII, VIII, VIIIC, IX, X, XI, XII, XIII, protein C, von Willebrand factor, Fitzgerald factor (prekallikrein), Fletcher factor (high molecular weight kininogen), and a proteinase inhibitor, such as aprotinin. An example of an aprotinin is Trasylol® (Miles, West Haven, CT), a saline solution of aprotinin containing 10,000 Kallikrein-Inhibitor Units (KIU)/ml. By the term "blood clotting factor" is meant a factor which accelerates, promotes, or allows the formation of a blood clot. Preferably, the blood clotting factor is present in an amount that results in a blood concentration in the subject of between 100 - 100,000 KIU/ml.

Oxygen-carrying solutions have been developed based on hemoglobin from human or animal sources, or made by genetic engineering, and modified by techniques such as crosslinking or the addition of polyethylene glycol (Spahn et al. (1994) Anesth. Analg. 78:1000-1021).

However, these solutions are toxic in high quantities. When a subject has lost blood, it would be advantageous to administer a blood substitute with a physiological or hyperphysiological oxygen-carrying capacity. Accordingly, in another aspect, the solution of the

- 4 -

invention includes an oxygen-carrying component. When the solution contains an oxygen-carrying component, such as cross-linked or high molecular weight hemoglobin, it may be desirable to reduce the amount of oncotic agent present such that colloid osmotic pressure approximately that of normal human serum, about 28 mm Hg. Preferably, the oxygen-carrying component is selected from the group consisting of hemoglobin or other respiratory pigments extracted from natural sources, such as hemocyanin, chlorocruorin, and hemerythrin, respiratory pigments made by recombinant DNA techniques, a crosslinked form of hemoglobin, and fluorocarbons. The oxygen-carrying component may be modified by methods known to the art, for example, a fluorocarbon component may be encapsulated by a liposome, and respiratory pigments altered by crosslinking or reaction with polyethylene glycol. By the term "oxygen-carrying component" is meant a component which forms an easily reversible interaction with oxygen, which allows more oxygen to be solubilized than would otherwise be possible, and that results in delivery of the excess oxygen to the tissue. A preferred oxygen-carrying component is hemoglobin, present in the concentration range of about between 20-200 g/l.

In a related aspect, the solutions of the invention are useful for harvesting and/or delivering red blood cells to patients in need thereof. Red blood cells for delivery may be obtained from a number of sources, including human donors, transgenic animals, or derived in vitro.

Plasma expanders and blood substitutes having two or more oncotic agents with differential clearance rates are particularly advantageous in providing extensive protection of oncotic pressure without inhibiting the subject's production of replacement plasma proteins. The

- 5 -

present invention includes solutions having two or more oncotic agents with differential clearance rates. By the term "differential clearance rates" is meant the rate at which a first oncotic agent is removed from the blood circulation is faster than the rate at which a second oncotic agent is removed.

The solutions of the present invention include physiological levels of a sugar. Preferably, the sugar is a simple hexose sugar such as glucose. By "physiological levels of a sugar" is meant a sugar concentration of between 2 mM to 50 mM. The preferred concentration of glucose is 5 mM.

Particular advantages of the solutions are that they are relatively inexpensive, contain components naturally occurring in the human body or which have been shown to be safe for use in the human body. The solutions of the present invention can be terminally heat sterilized, and can support life when replacing 50%-80% of a subject's blood at normal body temperature, or 100% of a subject's blood at hypothermic temperatures.

Detailed Description

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a formulation" includes mixtures of different formulations and reference to "the method of treatment" includes reference to equivalent steps and methods known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods

- 6 -

and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods and materials are now described. All publications mentioned herein are

- 5 incorporated herein by reference to describe and disclose specific information for which the reference was cited in connection with.

The present invention includes plasma expanders and blood substitutes suitable for use in mammals, including primates. The invention presented herein is in part described in USSN 08/253,384 filed June 3, 1994, USSN 08/133,527 filed October 7, 1993, and USSN 08/071,533, filed June 4, 1993, which applications are incorporated herein by reference. This invention is in part based on the discovery that because of the special species-specific physiology of primates, prior art plasma expanders and blood substitutes containing physiological or hyperphysiological potassium concentrations present disadvantages when used for near ice-cold blood-

10
15
20 substitution in primates.

Red blood cells of primates contain high concentrations of potassium ion (K^+). When primate blood is stored (as is the case with virtually all blood obtained from blood banks), even low levels of lysis of the red blood cells generally result in high potassium ion concentrations. This is due to release of potassium ion from inside the lysed primate red blood cells into the plasma surrounding the cells. Accordingly, the blood will be hyperkalemic when infused. The increased potassium level can be diffused if blood is infused into patients with sufficient circulating blood since the high potassium ion concentration is diluted. However, the problem increases if primate blood is transfused into a primate which has been perfused with a maintenance

25
30

- 7 -

solution of the type described in U.S. Patents 4,924,442, and 5,130,230, which contain high concentrations of potassium resulting in loading of the primate's tissues with excess potassium. The potassium ion concentration
5 in the transfused blood will not be diluted to safe levels. As a result, cardiac insufficiency may and frequently does occur. Hyperkalemia is also associated with tissue damage resulting from burns, accidents, surgery, chemotherapy, and other physical traumas. The
10 prior art teaches that organ preservation at low temperatures requires the presence of high potassium ion concentrations for the maintenance of tissue integrity.

The solution according to the present invention contains physiological or subphysiological amounts of
15 potassium. Thus, the solution allows for dilution of the potassium ion concentration in stored transfused blood. As a result, high concentrations of potassium ion and potential cardiac arrhythmias and cardiac insufficiency caused thereby can be more easily controlled. These
20 solutions are also useful for purposes of blood substitution and low temperature maintenance of a subject. By "physiological amount of potassium" is meant between 3.5 - 5 mEq/l K^+ (3.5 - 5 mM), preferably 4-5 mEq/l K^+ (4-5 mM). By "subphysiological amount of
25 potassium" is meant between 0-3.5 mEq/l K^+ (0-3.5 mM), preferably 2-3 mEq/l K^+ (2-3 mM).

The solution of the present invention comprises a mixture of materials which when placed in aqueous solution may be used to perfuse a subject in need
30 thereof. While the materials may be provided as a dry mixture to which water is added prior to heat sterilization or as a dry sterile mixture to which sterile water is added, the solution is preferably provided in the form of a sterile aqueous solution.

- 8 -

The solution of the present invention may be used as a single solution for all phases of procedures in which a subject's blood is removed and replaced or a subject is cooled. Such phases include hemodilution or
5 plasma extension at normal body temperatures, blood replacement and exchange at hypothermic body temperatures, blood substitution at substantially hypothermic body temperatures, and subject warming. "Hypothermic body temperatures" are defined as 3-5°C
10 below normal body temperatures of 37-38°C, e.g., about 32-35°C. "Substantially hypothermic body temperatures", also referred to as "near-ice cold" temperatures are defined as body temperatures just below the freezing point (-2°C) to about 10°C. Therefore, the term
15 "hypothermic body temperature" or "hypothermia" as used herein encompasses body temperatures of about -2 to 3°C to about 32-35°C.

The solution of the present invention does not include a conventional biological buffer. By
20 "conventional buffer" is meant a compound which in solution, *in vitro*, maintains pH at a particular range. By "conventional biological buffer" is meant a compound which in a cell-free system maintains pH in the biological range of 7-8. Examples of conventional
25 biological buffers include N-2-Hydroxyethylpiperazine-N'-2-hydroxypropanesulfonic acid (HEPES), 3-(N-Morpholino)propanesulfonic acid (MOPS), 2-([2-Hydroxy-1,1-bis(hydroxymethyl)ethyl]amino)ethanesulfonic acid (TES), 3-[N-tris(Hydroxy-methyl) ethylamino]-2-hydroxyethyl]-1-
30 piperazinepropanesulfonic acid (EPPS), Tris[hydroxymethyl]-aminomethane (THAM), and Tris[Hydroxymethyl]methyl aminomethane (TRIS). Conventional biological buffers function independently of normal biological processes, e.g., the conventional

- 9 -

buffer is not metabolized in vivo, and are most potent in cell-free systems.

The solution of the present invention uses normal biological components to maintain in vivo biological pH, a concept termed a "dynamic buffering system". The dynamic buffering system concept rests on the discovery by the inventors that compounds with no intrinsic buffering capacity in the biological range, such as lactate, acetate, or gluconate, capable of being metabolized in vivo, act with other solution components to maintain a biologically appropriate pH in an animal, even at hypothermic temperatures and at essentially bloodless conditions. The dynamic buffering system of the present invention depends in part on oxygenation and removal of carbon dioxide (CO_2); and allows but does not require additional bicarbonate (NaHCO_3). The dynamic buffer of the invention has no or substantially no ability to act as a buffer outside of a biological system, i.e., a dynamic buffer maintains pH in the biological range in vivo but not in a cell free environment.

A component of the dynamic buffering system of the invention include a carboxylic acid, salt or ester thereof. What is meant by a carboxylic acid, salt or ester thereof is a compound having the general structural formula RCOOX , where R is an alkyl, alkenyl, or aryl, branched or straight chained, containing 1 to 30 carbons which carbons may be substituted, and preferably one of the carbon chains that compose the carbon chain of lactate, acetate, gluconate, citrate, pyruvate, or other biological metabolites; and X is hydrogen or sodium or other biologically compatible ion substituent which can attach at the oxygen position.

- 10 -

The absence of a conventional biological buffer in the solution of the invention confers several important medical advantages. For example, lower concentrations of buffers consisting of normal biological components are required to maintain *in vivo* pH, compared to conventional biological buffers. Conventional biological buffers may also pose toxicity problems. Further, the absence of a biological buffer allows the solution to be terminally heat sterilized. Generally, medical solutions are preferred to be terminally heat sterilized prior to use in a patient. The term "terminally heat sterilized" or "heat sterilized" as used herein references to the process involving heating a solution to 120°C for 15 minutes under pressure, i.e., maintaining heat and pressure conditions for a period of time sufficient to kill all or substantially all bacteria and inactivate all or substantially all viruses in the solution. This procedure is normally performed in an autoclave, and is also known as "autoclaving". The purpose of heat sterilization is to kill possible infectious agents present in the solution. Infectious agents are known to tolerate temperatures up to 100°C. It is generally considered by the art that heating a solution under pressure to 120°C for about 15 minutes is sufficient to insure sterility. Governmental regulations may require heating a solution at even higher temperatures and pressures.

Transplant or blood substitute solutions containing proteins or a variety of organic compounds of which the inventors are aware cannot tolerate terminal heat sterilization at high temperatures and pressures. It is known that heat sterilizing a solution having containing carbohydrates or proteins, with a pH above

- 11 -

7.0, results in substantial degradation of solution components.

By contrast, the solution of the present invention is designed to be heat sterilizable with minimal degradation of other solution components, such as sugar. The solutions of the present invention are heat sterilized prior to use. When it is desirable to add components to the base solution, e.g., addition of NaHCO_3 to HL solution to form HLB solution for use under hypothermic conditions, NaHCO_3 is added as a commercially-available sterile 1 M solution to sterile HL solution. Generally, 5 ml of a 1 M NaHCO_3 solution is added per liter of HL solution to form 1 l of HLB solution. However, more NaHCO_3 may be added. Similarly, when it is desirable to add a blood clotting factor or oxygen-carrying component, the blood clotting factor or oxygen-carrying component is added as a sterile solution to the autoclaved base solution.

The HLB solution of the present invention, or its buffering organic acids and salts, may also be used to sustain cultured tissues and cells *in vitro*. The dynamic buffering system of the solution maintains cultured tissues and cells at the appropriate biological pH. We have shown that the addition of lactate and bicarbonate to cultured cells is sufficient to sustain normal cell growth and morphology.

The solution of the present invention includes an organic carboxylic acid or salt thereof. The term "organic carboxylic acid or salt thereof" includes any carboxylic acid or carboxylic acid derivative capable of being metabolized by the mammal. Examples of carboxylic acids and carboxylic acid salts suitable for use in the solution of the present invention include lactate and sodium lactate, citrate and sodium citrate, gluconate and

- 12 -

sodium gluconate, pyruvate and sodium pyruvate, succinate and sodium succinate, and acetate and sodium acetate. In the following Examples describing the use of HLB solution, sodium lactate is used. When metabolized in vivo, lactate helps maintain bicarbonate levels, and thereby functions as a component of the dynamic buffering system of the solution to maintain an in vivo biological pH.

For purposes of the further description of the invention, the mixture according to the invention will be discussed as an aqueous solution. From the following description of the invention, it is expected that one ordinarily skilled in the art would be enabled to provide the mixture as a dry mixture and make the adjustments to amounts of sodium chloride and organic salt of sodium as necessary to accommodate the amounts of sodium chloride found in normal saline solution, which may be used as a diluent for the dry mixture according to the invention.

The sodium ion concentration is preferably in a range from 70 mM to about 160 mM, and preferably in a range of about 130 to 150 mM.

The concentration of calcium ion is in a range of about 0.5 mM to 4.0 mM, and preferably in a range of about 2.0 mM to 2.5 mM.

The concentration of magnesium ion is in a range of 0 to 10 mM, and preferably in a range of about 0.3 mM to 0.45 mM. It is important not to include excessive amounts of magnesium ion in the solution according to the invention because high magnesium ion concentrations negatively affect the strength of cardiac contractile activity.

- 13 -

The concentration of chloride ion is in the range of 80 mM to 170 mM, preferably in the range of 110- 135 mM Cl⁻.

5 The solution also includes a physiological amount of simple hexose sugar such as glucose, fructose and galactose, of which glucose is preferred. In the preferred embodiment of the invention nutritive hexose sugars are used and a mixture of sugars can be used. The
10 term "physiological amount" or "physiological levels" means the concentration of sugar is in a range between 2 mM and 50 mM with concentration of glucose of 5 mM being preferred. At times, it is desirable to increase the concentration of hexose sugar in order to lower fluid
15 retention in the tissues of a subject. Thus the range of hexose sugar may be expanded up to about 50 mM if necessary to prevent or limit edema in the subject under treatment.

 The oncotic agent is comprised of molecules whose
20 size is sufficient to prevent their loss from the circulation by readily traversing the fenestrations of the capillary bed into the interstitial spaces of the tissues of the body. As a group, oncotic agents are exemplified by blood plasma expanders. Examples of
25 oncotic agents suitable for use in the solution of the present invention include human serum albumin, polysaccharides such as glucan polymers, and cross-linked or high molecular weight hemoglobin. Preferably, the polysaccharide is non-antigenic.

30 Hetastarch (McGaw, Inc.) is an artificial colloid derived from a waxy starch composed almost entirely of amylopectin with hydroxyethyl ether groups introduced into the alpha (1-4) linked glucose units. The colloid properties of a 6% solution (wt/wt) of Hetastarch

- 14 -

approximates that of human serum albumin. Other polysaccharide derivatives may be suitable as oncotic agents in the solutions according to the invention including hydroxymethyl alpha (1-4) or (1-6) polymers.

5 Cyclodextrins are suitable oncotic agents.

D-glucose polymers may be used. For example, dextran, which is D-glucose linked predominantly in alpha (1-6) linkage, may be used as the oncotic agent in the solution of the invention. Polysaccharides such as
10 dextran in a molecular weight range of 30,000 to 85,000 daltons (D) are preferred.

The concentration of the polysaccharide is sufficient to achieve (when taken together with chloride salts of sodium, calcium and magnesium, organic ion from
15 the organic salt of sodium and hexose sugar discussed above) colloid osmotic pressure approximating that of normal human serum, about 28 mm Hg.

In one aspect of the invention, the solution contains two or more oncotic agents with differential
20 clearance rates. Natural colloids, such as plasma proteins and human serum albumin, are useful for restoration of blood oncotic agent in a hypovolemic patient. However, natural colloids are expensive and in short supply. Also, they cannot be terminally sterilized
25 at high temperatures and pressures. Recombinant human albumin is under development, and may pose less of a threat in transmitting a pathogenic vector. However, this may also prove expensive to produce, and may present difficulties for sterilization and purity. Use of
30 artificial colloids overcome these deficiencies, with the important advantage of lessening the risk of transmitted disease. The solutions of the present invention having two or more oncotic agents with differential clearance rates provide additional advantages in restoring blood

- 15 -

oncotic pressure in a hypovolemic subject over an extended period of time, while encouraging the subject's own production of plasma proteins. Artificial oncotic agents with relatively slow clearance rates include high
5 molecular weight Hetastarch (molecular weight 300,000 - 1,000,000) and dextran 70, measured to have intravascular persistence rates of 6 hours (Messmer (1989) Bodensee Symposium on Microcirculation (Hammersen & Messmer, eds.), Karger, N.Y., pg. 59). Artificial oncotic agents
10 with relatively fast clearance rates include low molecular weight Hetastarch (average molecular weight 40,000-200,000) and dextran 40, having intravascular persistence rates of 2-3 hours (Messmer (1989) supra).

The solution may be used as a circulating solution
15 in conjunction with oxygen or hyperbaric oxygen at normal body temperatures, or with or without hyperbaric oxygen in subjects during procedures. The solution may also be used as a circulating solution in subjects during procedures when the subject's body temperature is reduced
20 significantly below the subject's normal temperature. When warm-blooded subjects are exposed to low temperature conditions during surgical procedures, it is generally desirable to replace the subject's blood with the cold circulating solution of the invention, or the solution
25 circulated for a time, designed to perfuse and maintain the subject and its organs intact during the procedure.

A subject undergoing blood substitution with the blood substitute of the present invention may be at risk for hemorrhage due to hemodilution. Under those
30 circumstances, it is advantageous to administer to the subject a blood clotting factor. Under emergency conditions when a subject has lost a considerable amount of blood and is continuing to bleed profusely, it is advantageous to administer a blood substitute solution

- 16 -

and a blood clotting factor with or following administration of the blood substitute. The solutions of the present invention may include a blood clotting factor able to accelerate or promote the formation of a blood
5 clot. The invention further encompasses a method of using the solutions of the present invention with administration of a blood clotting factor to a subject in need thereof. Preferred blood clotting factors for use in the solution of the invention include vitamin K,
10 Factors I, II, V, VII, VIII, VIIIIC, IX, X, XI, XII, XIII, protein C, von Willebrand factor, Fitzgerald factor, Fletcher factor, and a proteinase inhibitor. The concentration of the blood clotting factor is determined by one skilled in the art depending on the specific
15 circumstances of treatment. For example, generally when vitamin K is administered, its concentration will be sufficient to deliver 5 - 10 mg to the patient.

Oxygen-carrying compounds have been studied as a means for increase the oxygen-carrying capacity of a
20 subject. However, oxygen-carrying compounds in an effective amount have been shown to be toxic to the recipient subject. For example, administration of hemoglobin may result in kidney toxicity, stimulation of febrile and immunogenic responses, and stimulation of
25 bacterial growth. Administration of an effective amount of a fluorocarbon may interfere with lung function. The solutions of the present invention may include an oxygen-carrying component in a concentration sufficiently low so as not to be toxic to the subject. Oxygen-carrying
30 components include hemoglobin extracted from human and non-human sources, recombinant hemoglobin, hemocyanin, chlorocruorin and hemerythrin, and other naturally occurring respiratory pigments extracted from natural sources or made by recombinant DNA or in vitro methods.

- 17 -

These compounds may be modified by a number of means known to the art, including by chemical crosslinking or pegylation.

The solutions of the present invention may include

5 a sufficient amount of oxygen-carrying component to deliver enhanced oxygen to the tissues of a subject without resulting in toxicity to the subject. A "sufficient amount" of an oxygen-carrying component is an amount allowing a resting subject with an unimpaired

10 circulation and physiology to survive and recover from trauma, illness or injury. In normal humans at normal body temperature, this is at least 5-6 ml O₂/100 ml of intravascular fluid. When the oxygen-carrying component is hemoglobin, it is preferably present in the

15 concentration range of between about 20-200 g/l. The solution may be used in a variety of surgical settings and procedures. It may be useful in delicate neurosurgery where clear surgical fields are imperative and reduced central nervous system activity may be

20 desirable and achieved by performing the procedure on a patient whose core temperature and/or cerebral temperature has been substantially reduced. The solution may be used to maintain a subject (which has lost a significant amount of blood, e.g. 20% to 98% of its

25 blood) at normal body temperatures in a pressurized environment at increased oxygen concentration above atmospheric oxygen tension up to 100% oxygen. The subject is maintained in a high oxygen concentration until enough blood components can be synthesized by the

30 subject to support life at atmospheric pressure and oxygen concentration. The solution according to the invention may be used to maintain a subject at temperatures lower than normal body temperature and at a reduced rate of metabolism after traumatic life

- 18 -

threatening injury until appropriate supportive or corrective surgical procedures can be performed. In addition the solution may be used to maintain a patient having a rare blood or tissue type until an appropriate
5 matching donor can be found and replacement blood units or other organ can be obtained.

The procedure for replacing substantially all of a mammalian subject's circulating blood may be carried out with the mammalian subject's body temperature being
10 maintained at its substantially normal temperature. In addition the procedure may be carried out with cooling of the subject and reduction of the mammalian subject's body temperature below that of its normal temperature. Cooling may be accomplished by chilling the subject in an
15 ice bath, ice-salt slurry, or cooling blanket. The subject may be further cooled by chilling the solution according to the invention prior to perfusing the subject with the solution.

The solution is also suitable for use for
20 plasmapheresis. Plasmapheresis is a process in which all or a portion of the blood plasma is replaced while one or more groups of formed elements such as red blood cells or lymphocytes are retained. The blood plasma is removed by methods such as centrifugation or filtration. The
25 procedure allows removal of autoantibodies and other toxic agents. The solution of the invention may be used to replace the plasma fraction of the blood during the plasmapheretic procedure. This presents several distinct advantages. Blood plasma cannot be terminally sterilized
30 at high temperatures and pressures. Moreover, plasma is expensive and is sometimes unavailable. In some cases, it can provoke hypersensitivity reactions in patients. These problems are overcome by replacement of all or a portion of the removed plasma with the solutions of the

- 19 -

present invention. The solutions of the present invention are also suitable for use in lowering the body temperature of an organ or tissue donor, and as a blood replacement in organs and tissues harvested, stored, or
5 transported for transplantation.

The following Examples are intended to illustrate the invention and its use, and are not intended by the inventors to be limiting of the invention.

EXAMPLES

10 The following example is put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to carry out the synthesis of the invention and is not intended to limit the scope of what the inventors regard as their
15 invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.), but some experimental error and deviation should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average
20 molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

Example 1. Solution Compositions.

Composition of L solution. The composition of L solution is as follows: Na⁺ 143 mM; Ca⁺⁺ 2.5 mM; Mg⁺⁺
25 0.45 mM; K⁺ mM 3.0; Cl⁻ 124 mM; glucose 5 mM; and lactate 28 mM. The solution is filtered to remove undissolved material and placed in autoclavable containers and heated in an autoclave to a temperature of 120°C for 15 minutes.

Composition of HL (BioTime Hextend™-lactate)
30 Solution. To each liter of L solution, 60 g of high molecular weight Hetastarch is added. HL solution is

- 20 -

filtered and heat sterilized after the addition of
Hetastarch.

Composition of HLB (BioTime Hextend™-lactate-
bicarbonate) Solution. To each heat sterilized liter of
5 HL solution is added 5 ml of a sterile 1 M solution of
NaHCO₃, medical grade, forming HLB solution .

Composition of HL-DL (BioTime Hextend™-dextran-
lactate) Solution. DL solution was prepared with a
concentration of constituents identical to HL except 6%
10 Dextran 40 is used in place of 6% Hetastarch. DL-HL
solution was prepared by mixing an equal amount of DL and
HL solutions.

Composition of AL (BioTime Albextend) Solution.
AL solution is prepared by adding 5% sterile albumin to
15 sterilized L solution. ALB solution is prepared by
adding 5 ml of a sterile 1 M solution of NaHCO₃ to each
liter of AL solution.

Composition of HL-Heme Solution. To sterile HL
solution is added 20-200 g/l hemoglobin.

20 Example 2. Blood Replacement with HL-DL Solution.

A 240 g female rat was anesthetized with ketamine,
xylazine and acepromazine mixture injected i.m. The
animal was placed on a stage and its right femoral artery
and vein cannulated. The animal was perfused
25 isovolemically with 10 ml of HL-DL solution until its
hematocrit reached 17.2%. The cannulas were removed,
vessels ligated, and the incision closed. The animal
tolerated perfusion well, and was active and eating
within 3 days of the procedure. The animal remains alive
30 and healthy.

- 21 -

Example 3. Reviving An Ice-Cold Blood-Substituted Dog.

A 26.8 kg male dog was anesthetized with nembutal and intubated. It was moved to the operating room, ventilated, and catheterized with venous, Foley,
5 arterial, and Swan-Ganz catheters, and after i.v. heparin, its right femoral artery and vein were cannulated. An esophageal tube was inserted and antacid administered. Temperature sensors were placed in the esophagus and the rectum. Methyl prednisolone was
10 injected i.v.

The animal was wrapped in a cooling blanket, and surface cooling initiated. The animal's cannulas were connected to a bypass circuit, which consisted of a vortex blood pump, an oxygenator with a built-in heat
15 exchanger, a secondary in-line heat exchanger, and a funnel for the rapid administration of blood and blood substitute. Whole blood (225 ml) was removed from the dog and saved for rewarming. Blood volume was quickly replaced with HLB solution. The bypass circuit
20 containing 1.05 liters of HLB solution was opened to the animal, and core cooling began.

Thirty three liters of HLB solution were exchanged. By the time the ice-point was approached, the hematocrit was far below 1%. The animal's deep
25 esophageal temperature was below 10°C for 4 hours and 5 minutes, with a minimum recorded temperature of 0.7°C.

Following the hypothermic period, the animal was warmed. When body temperature climbed past 10°C, venous effluent and whole blood previously collected, as well as
30 donor blood, was returned to the circuit; hematocrit increased with increasing temperature. Lidocaine and bicarbonate were administered, the heart defibrillated, and ventilation begun. When blood pressure and body temperatures approached normal, the animal was weaned

- 22 -

from bypass, and protamine and Lasix injected. Several hours after warm-up, the animal was conscious and responsive. The animal remained alive and healthy after the procedure.

5 Example 4. Reviving an Ice-Cold Blood-Substituted Baboon.

A 24 kg male baboon of the species *Papio annubis* was anesthetized first with ketamine and acepromazine i.m., then with i.v. pentothal. It was then immobilized
10 with pancuronium bromide. It was intubated, ventilated, and catheterized with venous, Foley, and arterial catheters. The animal was wrapped in a cooling blanket, and surface cooling initiated. After i.v. heparin was administered, the baboon's right femoral artery and
15 bilateral femoral veins were cannulated. Temperature sensors were placed in the esophagus, rectum and brain. The animal was instrumented for EKG, somatosensory evoked potentials (SSEPs) and EEG. Dexamethazone was injected i.v.

20 The animal's cannulas were connected to a bypass circuit, which consisted of a vortex blood pump, an oxygenator with a built-in heat exchanger, and a funnel for the rapid administration of blood and blood substitute. Whole blood (300 ml) was removed from the
25 baboon and saved for rewarming. The volume was quickly replaced with 300 ml of physiological saline solution. The bypass circuit, containing 2 liters of Plasmalyte (commercially available electrolyte solution), was opened to the animal and core cooling begun.

30 After the deep esophageal temperature declined below 13°C, another 2 liters of Plasmalyte containing 12.5 g of mannitol, was added to the circuit, replacing the mixture of blood and Plasmalyte which previously

- 23 -

filled the circuit. This diluted blood was saved for use during warming. Immediately afterwards, 10 liters of HLB solution were added, replacing the Plasmalyte. By the time the ice-point was reached, the hematocrit was far
5 below 1%. When the animal reached brain temperature of 3.4°C and deep esophageal temperature of 2.8°C, the blood pump was stopped and the animal was maintained under a condition of circulatory arrest (standstill) for 45 minutes. After this period, circulation was resumed.

10 Following the hypothermic period, 4.2 liters of HLB solution were flushed through the animal while collecting venous effluent, and the animal warmed. When body temperature reached 15°C, 2 liters of Plasmalyte were added to the circuit to replace the HLB solution.

15 Mannitol (6.25 g/l) was added to the Plasmalyte in the circuit. Additionally, venous effluent and whole blood previously collected, as well as donor blood cells and fresh-frozen plasma, were returned to the circuit; the animal's hematocrit increased with increasing body
20 temperature. Another 12.5 g of mannitol were added to the circuit. When the esophageal and rectal temperatures approached normal, the heart fibrillated during warming and began beating. Ventilation was begun. When blood pressure and body temperatures approached normal, the
25 animal was injected with protamine i.v., weaned from bypass, its cannulas and catheters removed, and its incisions closed.

The animal's deep esophageal temperature had been below 15°C for 3 hours, and below 10°C for 2 hours 17
30 minutes, with a minimum recorded temperature of 2.8°C (Table 3). The following morning, the animal was able to sit erect in its cage and pick up and eat pieces of banana, as well as drink apple juice. It remained alive

- 24 -

and well until sacrificed more than one week later for histological evaluation.

Example 5. Blood Replacement with Two Solution System in a Patient Undergoing Cardiopulmonary Bypass Surgery.

5 A patient is anesthetized, cannulated and instrumented for cardiopulmonary bypass. The patient is wrapped in a cooling blanket and surface cooled to 30°C. The patient is then placed on bypass with the circuit primed with ALB solution. The patient is core and
10 surface cooled until his deep esophageal temperature reaches 20°C. Blood is collected with 4 L of ALB solution, and immediately replaced with HLB solution. The body is then cooled and maintained while surgical procedures and performed on the heart or brain. The
15 patient is then warmed, and the HLB solution replaced first with ALB solution, and then with the AL-blood solution originally removed. 5 - 10 mg of vitamin K is administered.

One of the advantage of using the ALB solution as
20 a bypass prime and for blood collection is that when the patient's own hemodiluted blood is reinfused during warm-up, albumin functions as the naturally-occurring compound, maintaining blood oncotic agent without impeding the patient's own ability to synthesize albumin.

25 Example 6. Emergency Blood-Substitution of Hemorrhaging Subject with HL-Heme Solution.

A patient suffering from severe blood loss is infused with HL solution containing 5 mg/l of blood-clotting factor vitamin K and 30 g/l of the oxygen-
30 carrying component hemoglobin. The patient's blood pressure is stabilized and normal oxygen delivery to the patient's tissues is resumed. The patient's body

- 25 -

gradually clears the Hetastarch component while synthesizing its own albumin such that blood oncotic pressure remains stabilized during the recovery period.

Use of HL solution containing blood-clotting factors and oxygen-carrying components allows the use of substitute blood to be reduced or completely avoided.

Example 7. Use of Blood Clotting Factor in Hemodiluted Mammals.

Six young female rats (227-262 g) were anesthetized, their right femoral arteries and veins cannulated, and 40-60% of their blood replaced with HL solution. After hematocrits were reduced to 16-22%, the animals were slowly injected i.v. with 6 ml of Trasylol® (10,000 KIU/ml). Their tails were severed 30 mm above the tip. Blood loss averaged 0.39 ± 0.06 (mean \pm SEM) ml, and all but one animal survived at least one day. Eight control animals were similarly perfused with HL solution, but were not given Trasylol® injections. The average blood loss was 4.8 ± 0.54 ml, and only 3 of the 8 animals survived. Compared to untreated controls, mortality ($P < 0.02$) and blood loss ($P < 0.002$) in the HL-treated animals without Trasylol® was significantly greater.

- 26 -

What is claimed is:

1. A blood substitute solution to replace all or
part of the blood of a mammal, comprising:
potassium, magnesium, sodium, calcium, and
5 chloride;
one or more water soluble oncotic agents;
and organic carboxylic acid or salt thereof; and
physiological amounts of a sugar;
with the proviso that said solution does not contain a
10 conventional biological buffer.
2. The solution of claim 1, wherein said mammal
is a primate.
3. The solution of claim 1, wherein said mammal
is maintained at hypothermic temperatures.
- 15 4. The solution of claim 1, wherein said
physiological amounts of a sugar are between about 0.5 mM
to 50 mM.
5. The solution of claim 1 further comprising a
blood clotting factor.
- 20 6. The solution of claim 5, wherein said blood
clotting factor is selected from the group consisting of
vitamin K, Factors I, II, V, VII, VIII, VIIIC, IX, X, XI,
XII, XIII, protein C, von Willebrand factor, Fitzgerald
factor, Fletcher factor, and aprotinin.
- 25 7. The solution of claim 1, further comprising
an oxygen-carrying component.

- 27 -

8. The solution of claim 7, wherein said oxygen-carrying component is selected from the group consisting of hemoglobin, fluorocarbon, hemocyanin, chlorocruorin, and hemerythrin.

5 9. The solution of claim 8, wherein said oxygen-carrying component is chemically modified.

10. The solution of claim 8, wherein said oxygen-carrying component is produced by recombinant DNA techniques.

10 11. The solution of claim 1 wherein said oncotic agents comprise first and second oncotic agents, wherein said first and second oncotic agents have differential clearance rates.

12. The solution of claim 1 wherein said oncotic
15 agents are selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, albumin, dextran 70, dextran 40, and mannitol.

13. A method of using a blood substitute solution
20 comprising potassium, magnesium, sodium, calcium, and chloride, one or more water soluble oncotic agents, an organic carboxylic acid or salt thereof, and physiological amounts of a sugar, with the proviso that said solution does not contain a conventional biological
25 buffer, said method comprising the steps of:

administering said blood substitute solution to a patient in need thereof; and

administering a blood clotting factor to said patient.

- 28 -

14. A method of using a blood substitute solution comprising potassium, magnesium, sodium, calcium, and chloride, one or more water soluble oncotic agents, an organic carboxylic acid or salt thereof, and
- 5 physiological amounts of a sugar, with the proviso that said solution does not contain a conventional biological buffer, said method comprising the steps of:
- administering said solution comprised of a first oncotic agent; and
- 10 administering said solution comprised of a second oncotic agent.

15. The solution of claim 14, wherein said first oncotic agent is mannitol.

16. The solution of claim 14, wherein said first
15 oncotic agent is low molecular weight dextran.

17. The solution of claim 14, wherein said first oncotic agent is albumin and said second oncotic agent is high molecular weight hydroxyethyl starch.

18. The solution of claim 14, wherein said first
20 oncotic agent is low molecular weight hydroxyethyl starch and said second oncotic agent is high molecular weight hydroxyethyl starch.

- 29 -

19. A method of using a solution for substituting the blood circulation volume of a primate, said solution comprising potassium, magnesium, sodium, calcium, and chloride, one or more water soluble oncotic agents, an
5 organic carboxylic acid or salt thereof, physiological amounts of a sugar, with the proviso that said solution does not contain a conventional biological buffer, said method comprising the steps of:

comprising withdrawing a volume of blood from
10 said subject while simultaneously infusing into said subject a volume of said solution.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/16680

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 1/02

US CL : 435/2, 1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/2, 1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------------------|---|--|
| X -- Y | US, A, 5,374,624 (SEGEL) 20 December 1994, see especially Table 1 and abstract. | 1-4, 7-9, 11-19 ----- 5, 6, 10 |
| X, P ----- Y, P | US, A, 5,407,428 (SEGALL et al.) 18 April 1995, see abstract and column 10, lines 34-48. | 1-6, 11-14, 16-19 ----- 7-10, 15 |
| X | A. L. Lehninger, "PRINCIPLES OF BIOCHEMISTRY", published 1982 by Worth Publishers, Inc., pages 705-713, see page 706. | 1-5, 11, 12 |

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| *A* document defining the general state of the art which is not considered to be part of particular relevance | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| *E* earlier document published on or after the international filing date | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *Z* document member of the same patent family |
| *O* document referring to an oral disclosure, use, exhibition or other means | |
| *P* document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

15 APRIL 1996

Date of mailing of the international search report

30 APR 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SANDRA SAUCIER

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/16680

| C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|---|--|-----------------------|
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| Y | US, A, 3,937,821 (IRIKURA et al.) 10 February 1976, see abstract. | 1-19 |
| Y | Clinical Pharmacy, Volume 12, issued May 1993, Wagner et al., "DRUG REVIEW: Pharmacologic and clinical considerations in selecting crystalloid, colloidal, and oxygen-carrying resuscitation fluids, part 1", pages 335-346, see abstract. | 1-19 |
| Y | Hammersen & Messmer, eds. "Bodensee Symposium on Microcirculation", published 1988 by Karger (N.Y.), Messmer K., "Characteristics, effects and side-effects of plasma substitutes" pages 52-70, see page 53. | 1-19 |

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

THIS PAGE BLANK (USPTO)